BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection display great variability in disease activity and progression. Although virus-specific adaptive immune responses have been characterized extensively and found to be impaired in chronic hepatitis C, the role of innate immune responses in disease activity and progression of chronic hepatitis C is not well understood. METHODS: We studied 42 HCV-infected patients and 12 healthy uninfected controls. RESULTS: We found an increased frequency of natural killer (NK) cells expressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), NKp44, NKG2C, and CD122 in chronic hepatitis C as compared with healthy controls (P < .05 for all markers) and stronger activation of NK cells in the liver than in the blood (P < .05). This NK cell phenotype was associated with polarization of NK cell function toward CD107a expression as a marker of degranulation, but with not increased interferon (IFN)-gamma production of CD56(dim) NK cells. The polarized NK cell phenotype correlated with alanine aminotransferase levels (r(2) = 0.312, P = .03). To investigate whether in vivo exposure of NK cells to HCV-induced type I IFN was causing this NK cell phenotype, peripheral blood mononuclear cells from 10 healthy controls and 8 HCV-infected patients were stimulated in the presence of IFN-alfa, which resulted in increased NK cell expression of TRAIL and CD107a (P < .001), but not IFN-gamma. CONCLUSIONS: Collectively, these results describe a polarized NK cell phenotype induced by chronic exposure to HCV-induced IFN-alfa. This phenotype may contribute to liver injury through TRAIL expression and cytotoxicity, whereas the lacking increase in IFN-gamma production may facilitate the inability to clear HCV. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
BACKGROUND & AIMS:Patients with chronic hepatitis C virus (HCV) infection display great variability in disease activity and progression. Although virus-specific adaptive immune responses have been characterized extensively and found to be impaired in chronic hepatitis C, the role of innate immune responses in disease activity and progression of chronic hepatitis C is not well understood. METHODS: We studied 42 HCV-infectedpatients and 12 healthy uninfected controls. RESULTS: We found an increased frequency of natural killer (NK) cells expressing tumornecrosis factor-related apoptosis-inducing ligand (TRAIL), NKp44, NKG2C, and CD122 in chronic hepatitis C as compared with healthy controls (P < .05 for all markers) and stronger activation of NK cells in the liver than in the blood (P < .05). This NK cell phenotype was associated with polarization of NK cell function toward CD107a expression as a marker of degranulation, but with not increased interferon (IFN)-gamma production of CD56(dim) NK cells. The polarized NK cell phenotype correlated with alanine aminotransferase levels (r(2) = 0.312, P = .03). To investigate whether in vivo exposure of NK cells to HCV-induced type I IFN was causing this NK cell phenotype, peripheral blood mononuclear cells from 10 healthy controls and 8 HCV-infectedpatients were stimulated in the presence of IFN-alfa, which resulted in increased NK cell expression of TRAIL and CD107a (P < .001), but not IFN-gamma. CONCLUSIONS: Collectively, these results describe a polarized NK cell phenotype induced by chronic exposure to HCV-induced IFN-alfa. This phenotype may contribute to liver injury through TRAIL expression and cytotoxicity, whereas the lacking increase in IFN-gamma production may facilitate the inability to clear HCV. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Authors: K M Chang; R Thimme; J J Melpolder; D Oldach; J Pemberton; J Moorhead-Loudis; J G McHutchison; H J Alter; F V Chisari Journal: Hepatology Date: 2001-01 Impact factor: 17.425
Authors: Salim I Khakoo; Chloe L Thio; Maureen P Martin; Collin R Brooks; Xiaojiang Gao; Jacquie Astemborski; Jie Cheng; James J Goedert; David Vlahov; Margaret Hilgartner; Steven Cox; Ann-Margeret Little; Graeme J Alexander; Matthew E Cramp; Stephen J O'Brien; William M C Rosenberg; David L Thomas; Mary Carrington Journal: Science Date: 2004-08-06 Impact factor: 47.728
Authors: Andrew I Su; John P Pezacki; Lisa Wodicka; Amy D Brideau; Lubica Supekova; Robert Thimme; Stefan Wieland; Jens Bukh; Robert H Purcell; Peter G Schultz; Francis V Chisari Journal: Proc Natl Acad Sci U S A Date: 2002-11-19 Impact factor: 11.205
Authors: Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari Journal: Proc Natl Acad Sci U S A Date: 2002-11-19 Impact factor: 11.205
Authors: Heiner Wedemeyer; Xiao-Song He; Michelina Nascimbeni; Anthony R Davis; Harry B Greenberg; Jay H Hoofnagle; T Jake Liang; Harvey Alter; Barbara Rehermann Journal: J Immunol Date: 2002-09-15 Impact factor: 5.422
Authors: Philipp A Lang; Karl S Lang; Haifeng C Xu; Melanie Grusdat; Ian A Parish; Mike Recher; Alisha R Elford; Salim Dhanji; Namir Shaabani; Charles W Tran; Dilan Dissanayake; Ramtin Rahbar; Magar Ghazarian; Anne Brüstle; Jason Fine; Peter Chen; Casey T Weaver; Christoph Klose; Andreas Diefenbach; Dieter Häussinger; James R Carlyle; Susan M Kaech; Tak W Mak; Pamela S Ohashi Journal: Proc Natl Acad Sci U S A Date: 2011-12-13 Impact factor: 11.205
Authors: Elisavet Serti; Jens M Werner; Michael Chattergoon; Andrea L Cox; Volker Lohmann; Barbara Rehermann Journal: Gastroenterology Date: 2014-03-28 Impact factor: 22.682
Authors: Chelsey J Judge; Lenche Kostadinova; Kenneth E Sherman; Adeel A Butt; Yngve Falck-Ytter; Nicholas T Funderburg; Alan L Landay; Michael M Lederman; Scott F Sieg; Johan K Sandberg; Donald D Anthony Journal: J Leukoc Biol Date: 2017-04-11 Impact factor: 4.962